GHRP-6 Acetate 5mg

Research

Scientific Research on GHRP-6 (Growth Hormone Releasing Peptide-6)
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide developed in the 1980s as a growth hormone secretagogue. Its sequence is:
His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
It was one of the first peptides identified capable of stimulating GH secretion independently of the classical GHRH pathway. Subsequently, it was demonstrated that its action occurs via activation of the ghrelin receptor (GHS-R1a).

Mechanism of Action and Inhibition

GHRP-6 acts as an agonist of the GHS-R1a receptor, a G protein-coupled receptor (GPCR).
Molecular cascade:

• Binding to GHS-R1a
• Activation of Gq/11 protein
• Stimulation of phospholipase C (PLC)
• Formation of IP3 and DAG
• Increase in intracellular calcium
• Exocytosis of GH by somatotroph cells

Additional effects:

• Partial suppression of somatostatin activity
• Synergy with GHRH
• Stimulation of prolactin and ACTH secretion
• Appetite stimulation via hypothalamic action

It exhibits no primary inhibitory action; its effect is predominantly agonist.

Scientifically Investigated Metabolic Impacts

Experimental GHRP-6 administration results in:
GH/IGF-1 axis

• Acute GH increase
• Subsequent IGF-1 elevation (with repeated administration)

Lipid metabolism

• Lipolysis stimulation (GH-mediated)
• Potential adipose tissue reduction with prolonged use

Carbohydrate metabolism

• Possible transient insulin sensitivity reduction
• Discreet blood glucose increase in some models

Appetite and food intake
GHRP-6 exhibits more pronounced orexigenic effects than GHRP-2, possibly due to central activation of ghrelin-associated pathways (NPY/AgRP).

Investigation in Oncological Models

GH/IGF-1 axis activation may:

• Stimulate proliferative pathways (PI3K/Akt/mTOR)
• Modulate cell survival
• Influence angiogenesis

However, there is no consolidated evidence of GHRP-6 use as an oncological therapeutic agent. Its oncological interest relates primarily to implications of chronic somatotrophic axis activation.
Experimental models suggest persistent IGF-1 increases may influence tumor microenvironment, but data are indirect.

Pharmacokinetic Considerations in Research

• Administration: subcutaneous, intravenous, or intraperitoneal in experimental models
• Short plasma half-life
• GH peak between 15–60 minutes post-administration
• Rapid degradation by systemic peptidases

Response may undergo desensitization with continuous administration.

Other Important Existing Research Relationships

• GH deficiency studies
• Experimental sarcopenia investigation
• Aging models
• Appetite regulation and energy balance
• Hypothalamus-pituitary-adrenal axis modulation
  Also studied as a tool for pituitary functional assessment.

Final Considerations

GHRP-6 is a synthetic hexapeptide GH secretagogue acting via GHS-R1a receptor activation, sharing central mechanism with GHRP-2. However, it exhibits lower secretagogue potency and greater orexigenic effect.
In research, it remains relevant as a tool for somatotrophic axis study, neuroendocrine regulation, and energy metabolism. Chronic GH/IGF-1 axis activation requires careful evaluation due to potential systemic proliferative implications.

References

Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545. https://doi.org/10.1210/endo-114-5-1537
Smith, R. G., Cheng, K., Schoen, W. R., et al. (1993). A nonpeptidyl growth hormone secretagogue. Science, 260(5111), 1640–1643. https://doi.org/10.1126/science.8503003
Kojima, M., Hosoda, H., Date, Y., et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. https://doi.org/10.1038/45230
Arvat, E., Di Vito, L., Broglio, F., et al. (1997). Preliminary evidence that GHRP-6 stimulates GH secretion through a mechanism independent of GHRH. Journal of Endocrinological Investigation, 20(8), 514–518. https://doi.org/10.1007/BF03347991

Scientific Reviewer
Content reviewed by Dr. Ky H. Le, MD. Dr. Ky H. Le is a family physician in Aiea, Hawaii. He received his medical degree from St. George's University School of Medicine and has been practicing for over 20 years. He has expertise in treating obesity, diabetes, hypertension, and high blood pressure, among other conditions—see all areas of specialization. Dr. Ky H. Le accepts Medicare, Aetna, Humana, Blue Cross, United Healthcare.
Ref.: https://health.usnews.com/doctors/ky-le-371599#expertise